Advertisement

Pharmacy World & Science

, Volume 32, Issue 4, pp 440–448 | Cite as

An evaluation of consumers’ knowledge, perceptions and attitudes regarding generic medicines in Auckland

  • Zaheer-Ud-Din BabarEmail author
  • Joanna Stewart
  • Shiwangni Reddy
  • Woroud Alzaher
  • Prateeka Vareed
  • Nineweh Yacoub
  • Bandhana Dhroptee
  • Anne Rew
Research Article

Abstract

Objectives The aim of this project was to evaluate the perceptions, knowledge and attitudes regarding generic medicines. Methods A cross-sectional study, with self administered questionnaires, was conducted to survey consumers visiting pharmacies in four regions of Auckland (North Shore, Waitakere, Central Auckland and South Auckland). Through stratified random sampling, approximately 10% of pharmacies from each region were selected, which turn out to be 30 pharmacies. Every alternate customer coming to the pharmacy, who was eligible to participate in the study, was asked by the researchers to complete the questionnaire. Results A total of 441 questionnaires were included in the analysis. Different response rates were obtained in different regions of Auckland. Of all respondents, 51.6% had previous knowledge of generic medicines. Pharmacists were the main source of information regarding generic medicines followed by doctors and media. A higher level of education had a direct relationship with having correct knowledge of generics (P = .002). Attitude of participants toward the use of generic medicines was determined by their knowledge of generics, whether it was recommended by a pharmacist and their type of illness. Participants were more prepared to change to a generic for a minor illness (79%) than for a major illness (58.7%). Those who had better knowledge were more likely than those with poor knowledge to say they would to use a generic in major illness (P = .001) as well as minor illness (P < .0001). Previous positive experiences with generics also determined consumers’ willingness to use generics. Conclusion Many consumers have misconceptions regarding generic medicines. Having knowledge about generics and the advice by doctors and pharmacists are key indicators to improve the quality use of generic medicines.

Keywords

Attitudes Auckland Consumers Generic medicines Opinions 

Notes

Acknowledgement

We would like to say thanks to Ms Rachelle Reber and the two anonymous reviewers.

Funding

The researchers’ travelling expenses were paid by the School of Pharmacy, University of Auckland.

Conflicts of interest

None.

References

  1. 1.
    Glover J, Hetzel D, Tennant S. Australia and New Zealand, health systems of international encyclopedia of public health. Oxford: Academic Press; 2008. p. 255–67.Google Scholar
  2. 2.
    Organization of Economic Cooperation and Development (OECD) Health Data 2008—Version June 2008. http://www.oecd.org/dataoecd/46/36/38979632.xls. Accessed 20 Sept 2009.
  3. 3.
    PHARMAC. Pharmaceutical Management Agency Annual Review, New Zealand Government. 2007. http://www.pharmac.govt.nz/2007/11/21/ARev071.pdf. Accessed 15 Sept 2009.
  4. 4.
    Williams G, Poynton M. PHARMAC: getting the best bang for your buck since 1993—pharmacy 409 lecture. New Zealand: University of Auckland; 2009.Google Scholar
  5. 5.
    Kanavos P. Do generics offer significant savings to the UK National Health Service? Curr Med Res Opin. 2007;23(1):105–16.CrossRefPubMedGoogle Scholar
  6. 6.
    King DR, Kanavos P. Encouraging the use of generic medicines: implications for transition economies. Croat Med J. 2002;43(4):462–9.PubMedGoogle Scholar
  7. 7.
    Meyer MC. United States Food and Drug Administration requirements for approval of generic drug products. J Clin Psychol. 2001;62(5):4–9.Google Scholar
  8. 8.
  9. 9.
    Medsafe [Homepage on the Internet]. Information for health professionals. Interchangeable status (IMM). Wellington: New Zealand Medicines and Medical Devices Safety Authority 2006. http://www.medsafe.govt.nz/profs/imm.asp. Accessed 17 Sept 2009.
  10. 10.
    Medsafe [Homepage on the Internet]. Information for consumers. How medicines are regulated. Wellington: New Zealand Medicines and Medical Devices Safety Authority. http://www.medsafe.govt.nz/consumers/regulate.asp. Accessed 16 Sept 2009.
  11. 11.
    Medsafe. New Zealand regulatory guidelines for medicines. vol 1, 6.3 ed. Wellington: Medsafe. 2009. http://medsafe.govt.nz/regulatory/Guideline/Full%20-%20NZ%20Regulatory%20Guidelines%20for%20Medicines.pdf. Accessed 19 Sept 2009.
  12. 12.
    Meredith PA. Generic drugs. Therapeutic equivalence. Drug Saf. 1996;15(4):233–42.CrossRefPubMedGoogle Scholar
  13. 13.
    Meredith P. Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther. 2003;25(11):2875–90.CrossRefPubMedGoogle Scholar
  14. 14.
    Minutes of the PHARMAC Consumer Advisory Committee (CAC) Meeting, Friday 13 July 2007. Wellington, New Zealand: PHARMAC. http://www.pharmac.govt.nz/pdf/021007a.pdf. Accessed 18 Sept 2009.
  15. 15.
    Generic Medicines: Dealing with Mutliple Brands. National Prescribing Service Newsletter. NPS News 55. 2007. http://www.nps.org.au/__data/assets/pdf_file/0008/23867/news55.pdf. Accessed 15 Sept 2009.
  16. 16.
    Borgheini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoative drugs. Clin Ther. 2003;25(6):1578–92.CrossRefPubMedGoogle Scholar
  17. 17.
    Ministry of Health. Primary health care: pharmaceutical co-payments. 2007. http://www.moh.govt.nz/moh.nsf/indexmh/phcs-funding-pharmaceutical. Accessed 17 Sept 2009.
  18. 18.
    Medsafe [Homepage on the Internet]. Information for health professionals. Regulatory issues. No immediate change to generic. Wellington: New Zealand Medicines and Medical Devices Safety Authority. http://www.medsafe.govt.nz/profs/riss/gensubleg.asp#No. Accessed 17 Sept 2009.
  19. 19.
    Upfront: Brand Change. Changing to a generic drug. BPac NZ. 2007. http://www.bpac.org.nz/magazine/2007/june/upfront.asp. Accessed 1 May 2008.
  20. 20.
    Al-Gedadi NA, Hassali MA, Shafie AA. A pilot survey on perceptions and knowledge of generic medicines among consumers in Penang, Malaysia. Pharm Pract. 2008;6(2):93–7.Google Scholar
  21. 21.
    Babar ZU, Awaisu A. Evaluating community pharmacists, perception and practices on generic medicines: a pilot study from peninsular Malaysia. J Gen Med. 2008;5:315–30.CrossRefGoogle Scholar
  22. 22.
    Ministry of Health. Towards a New Zealand medicines strategy consultation document. 2006. http://www.moh.govt.nz/moh.nsf/pagesmh/5633. Accessed 14 June 2010
  23. 23.
    Statistics New Zealand. Demographic trends: 2007. Wellington: Statistics New Zealand. 2008. http://search.stats.govt.nz/search?p=Q&ts=custom&w=demographics. Accessed 14 June 2010
  24. 24.
    Latin American conference on economic aspects of essential medicines. World Health Organisation; 1992.Google Scholar
  25. 25.
    Kjoenniksen I, Lindbaek M, Granas AG. Patients’ attitudes towards and experiences of generic drug substitution in Norway. Pharm World Sci. 2006;28(5):284–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Åstrand B, Hovstadius B, Antonov K, Petersson G. The Swedish national pharmacy register. Stud Health Technol Inform. 2007;129:345–9.PubMedGoogle Scholar
  27. 27.
    Tolonen H, Helakorpi S, Talala K, Helasoja V, Martelin T, Prättälä R. 25-year trends and socio-demographic differences in response rates: Finnish adult health behaviour survey. Eur J Epidemiol. 2006;21(6):409–15.CrossRefPubMedGoogle Scholar
  28. 28.
    Gaither CA, Kirking DM, Ascione FJ, Welage LS. Consumers’ views on generic medications. J Am Pharm Assoc. 2001;41(5):729–36.Google Scholar
  29. 29.
    Sansgiry SS, Bhosle M, Pope N. Consumer perceptions regarding generic drug substitution: an exploratory study. J Pharm Mark Manag. 2005;17(1):77–91.CrossRefGoogle Scholar
  30. 30.
    Suh DC. Trends of generic substitution in community pharmacies. Pharm World Sci. 1999;21(6):260–5.CrossRefPubMedGoogle Scholar
  31. 31.
    Valles JA, Barreiro M, Cereza G, et al. A prospective multicenter study of the effect of patient education on acceptability of generic prescribing in general practice. Health Policy. 2003;65(3):269–75.CrossRefPubMedGoogle Scholar
  32. 32.
    Heikkilä R, Mäntyselkä P, Hartikainen HK, Ahonen R. Customers’ and physicians’ opinions of and experiences with generic substitution during the first year in Finland. Health Policy. 2007;82(3):366–74.CrossRefPubMedGoogle Scholar
  33. 33.
    Mott DA, Cline RR. Exploring generic drug use behavior: the role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution. Med Care. 2002;40(8):662–74.CrossRefPubMedGoogle Scholar
  34. 34.
    Banahan BF, Kolassa EM. A physician survey on generic drugs and substitution of critical dose medications. Arch Intern Med. 1997;157(18):2080–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Ganther JM, Kreling DH. Consumer perceptions of risk and required cost savings for generic prescription drugs. J Am Pharm Assoc (Wash). 2000;40(3):378–83.Google Scholar
  36. 36.
    Palagyi M, Lassanova M. Patients attitudes towards experience with use of generics in Slovakia, performance of generic substitution. Bratisl Lek Listy. 2008;109(7):324–8.PubMedGoogle Scholar
  37. 37.
    Hassali MA, Kong D, Stewart K. Generic medicines: perceptions of consumers in Melbourne, Australia. Int J Pharm Pract. 2005;13(4):257–64.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Zaheer-Ud-Din Babar
    • 1
    Email author
  • Joanna Stewart
    • 2
  • Shiwangni Reddy
    • 1
  • Woroud Alzaher
    • 1
  • Prateeka Vareed
    • 1
  • Nineweh Yacoub
    • 1
  • Bandhana Dhroptee
    • 1
  • Anne Rew
    • 1
  1. 1.School of Pharmacy, Faculty of Medical and Health SciencesUniversity of AucklandAucklandNew Zealand
  2. 2.School of Population Health, Faculty of Medical and Health SciencesUniversity of AucklandAucklandNew Zealand

Personalised recommendations